News & Updates

Show Multimedia Only

Systemic fluoroquinolone treatment not a risk factor for uveitis, retinal detachment

28 Jul 2024

Individuals who received systemic fluoroquinolone do not appear to have an increased risk of uveitis or retinal detachment, as shown in a study.

Systemic fluoroquinolone treatment not a risk factor for uveitis, retinal detachment

28 Jul 2024

Disrupted circadian rhythm a modifiable risk factor for Alzheimer’s disease?

28 Jul 2024 by

Circadian rhythm disruption appears to precede the accumulation of amyloid-beta plaques and potentially represents a modifiable risk factor for Alzheimer's disease (AD), according to a study.

Disrupted circadian rhythm a modifiable risk factor for Alzheimer’s disease?

28 Jul 2024

Is sugammadex better than neostigmine for preventing postoperative complications?

28 Jul 2024 by

Treatment with sugammadex for the reversal of neuromuscular blockade falls short of significantly reducing the risk of postoperative pulmonary complications (PPCs) when compared with neostigmine, as shown in a recent study.

Is sugammadex better than neostigmine for preventing postoperative complications?

28 Jul 2024

Re-esterified triglyceride omega-3 trial yields null results for dry eye disease

28 Jul 2024

Supplementation with the re-esterified triglyceride (rTG) form of omega-3 fatty acid does not help ameliorate the symptoms of dry eye disease (DED) associated with meibomian gland dysfunction, as shown in a study.

Re-esterified triglyceride omega-3 trial yields null results for dry eye disease

28 Jul 2024

Adults with schizophrenia get long-term benefits with paliperidone palmitate

27 Jul 2024 by

More than 90 percent of adult patients with schizophrenia who continued to receive the long-acting injectable (LAI) antipsychotic paliperidone palmitate for another 2 years after completing a 1-year treatment course remained relapse-free, with no new safety signals emerging, according to an open-label extension (OLE) study.

Adults with schizophrenia get long-term benefits with paliperidone palmitate

27 Jul 2024

Vibegron relieves OAB symptoms in men treated for BPH

27 Jul 2024 by

Treatment with vibegron significantly improves overactive bladder (OAB) symptoms in men who are being treated for benign prostatic hyperplasia (BPH), including daily micturitions and urgency episodes, results from the phase III COURAGE trial have shown. It is well tolerated and has an acceptable safety profile, with adverse event (AE) rates similar to placebo.

Vibegron relieves OAB symptoms in men treated for BPH

27 Jul 2024

DHA, vitamin E of no benefit in MASLD

27 Jul 2024

In the treatment of adults with metabolic dysfunction–associated steatotic liver disease (MASLD), the use of docosahexaenoic acid (DHA), vitamin E, or its combination stops short of reducing liver fat or aminotransferases, according to a study.

DHA, vitamin E of no benefit in MASLD

27 Jul 2024

Dual trigger as good as GnRHa alone trigger for mature oocyte retrieval

27 Jul 2024 by

Dual triggering with gonadotropin-releasing hormone agonist (GnRHa) and human chorionic gonadotropin (hCG) was not superior to GnRHa alone in terms of mature oocyte retrieval for elective fertility preservation, according to a study presented at ESHRE 2024.

Dual trigger as good as GnRHa alone trigger for mature oocyte retrieval

27 Jul 2024

Menopause linked to bladder woes

26 Jul 2024

Overactive bladder (OAB) is common among women undergoing menopause, especially among those at late menopausal stage and who have other menopausal symptoms, as reported in a cross-sectional study.

Menopause linked to bladder woes

26 Jul 2024

Galcanezumab a safer choice than prednisone for medication overuse headache

26 Jul 2024 by

Both galcanezumab and prednisone effectively relieve pain in people with medication overuse headache (MOH), with combination therapy using both medications yielding the greatest benefit, according to the results of a three-arm, head-to-head observational study. However, the use of prednisone is accompanied by an increased frequency of adverse events.

Galcanezumab a safer choice than prednisone for medication overuse headache

26 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Systemic fluoroquinolone treatment not a risk factor for uveitis, retinal detachment

Systemic fluoroquinolone treatment not a risk factor for uveitis, retinal detachment

Disrupted circadian rhythm a modifiable risk factor for Alzheimer’s disease?

Disrupted circadian rhythm a modifiable risk factor for Alzheimer’s disease?

Is sugammadex better than neostigmine for preventing postoperative complications?

Is sugammadex better than neostigmine for preventing postoperative complications?

Re-esterified triglyceride omega-3 trial yields null results for dry eye disease

Re-esterified triglyceride omega-3 trial yields null results for dry eye disease

Adults with schizophrenia get long-term benefits with paliperidone palmitate

Adults with schizophrenia get long-term benefits with paliperidone palmitate

Vibegron relieves OAB symptoms in men treated for BPH

Vibegron relieves OAB symptoms in men treated for BPH

DHA, vitamin E of no benefit in MASLD

DHA, vitamin E of no benefit in MASLD

Dual trigger as good as GnRHa alone trigger for mature oocyte retrieval

Dual trigger as good as GnRHa alone trigger for mature oocyte retrieval

Menopause linked to bladder woes

Menopause linked to bladder woes

Galcanezumab a safer choice than prednisone for medication overuse headache

Galcanezumab a safer choice than prednisone for medication overuse headache